Trial Site Detail
Drug: |
Rogaratinib |
|||
|---|---|---|---|---|
Trial: |
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) |
|||
| Conditions: | Sarcoma | |||
Trial Status: |
Active, not recruiting |
|||
Vanderbilt-Ingram Cancer Center2220 Pierce Ave. 691 Preston Building |
Principal Investigator: |
Elizabeth J. Davis |
|---|---|
Contact: |
Contact: Site Public Contact 800-811-8480 |
Activation Status of this Site: |
Active |
Notes about this Site: |
|
Vanderbilt-Ingram Cancer Center Website: |
http://www.vicc.org/ct/ |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.